Maribavir
- TRADE NAME: Livtencity (Takeda)
- INDICATIONS: Treatment of cytomegalovirus disease/infection.
- HALF-LIFE: 4 hours
FDA APPROVAL DATE: 11/23/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Carbamazepine, Cyclosporine, CYP3A4 inducers, Digoxin, Everolimus, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rosuvastatin, Sirolimus, St John's Wort, Tacrolimus
No adequate human data currently available to establish if there is a risk to pregnancy outcomes.
Maribavir is not recommended to be co-administered with valganciclovir/ganciclovir.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric